Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 24 2024 - 4:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of May 2024 (Report No. 3)
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On
May 22, 2024, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: “NLS Pharmaceutics Announces Receipt of
Additional Staff Delisting Determination from Nasdaq.” A copy of this press release is furnished herewith as Exhibit 99.1.
This
report is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-262489, and 333-268690 and 333-269220),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
NLS Pharmaceutics Ltd. |
|
|
|
Date: May 24, 2024 |
By: |
/s/ Alexander Zwyer |
|
|
Name: |
Alexander Zwyer |
|
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting
Determination from Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics
Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused
on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced
that on May 22, 2024, the Company received an additional staff determination letter (the “Letter”) from the staff (the “Staff”)
of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it did not comply
with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Listing Rule 5550(b), and that the
additional delinquency may serve as a separate basis for the delisting of the Company’s securities from Nasdaq.
On April 19, 2024, the Company was previously notified by the Staff
that its securities were subject to delisting unless it timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”),
due to the Company’s failure to maintain at least a $1 bid price per share over the course of 30 consecutive business days, as set forth
in Nasdaq Listing Rule 5550(a)(2). In addition, on January 9, 2024, the Company received a letter from the Staff that it was no longer
in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. On February 23, 2024,
the Company announced that it had submitted a plan to regain compliance with the stockholders’ equity requirement.
The Company has requested a hearing before the Nasdaq Hearings Panel
to appeal the Staff’s delisting determination and intends to present its views and planned measures to cure the deficiencies mentioned
herein at its hearing with the Nasdaq Hearings Panel, scheduled to occur on June 4, 2024.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical
company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex
central nervous system disorders. The Company’s lead product candidate, Quilience®, is a proprietary extended-release formulation
of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic
hypersomnia (IH), for which NLS recently obtained Orphan Disease Designation (ODD) from the European Medicines Agency (EMA). Mazindol
is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed
with narcolepsy in compassionate use programs. A Phase 2a multi-center U.S. clinical trial evaluating Quilience® in adult
subjects suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and
tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol® (Mazindol Controlled-Release)
in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated.
Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to
1/3 of narcoleptic patients are also diagnosed with ADHD.
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially
from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles
in launching and/or successfully completing its clinical trials; NLS’ products may not be approved by regulatory agencies, NLS’ technology
may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain
or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop
with NLS’ process; NLS’ products may wind up being more expensive than it anticipates; results in the laboratory may not translate to
equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials;
NLS’ patents may not be sufficient; NLS’ products may harm recipients; changes in legislation may adversely impact NLS; inability to timely
develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under the heading “Risk Factors” in NLS’ annual report on Form
20-F for the year ended December 31, 2023 filed with the SEC, which is available on the SEC’s website, www.sec.gov, and in subsequent
filings made by NLS with the SEC.
Investor Relations Contact
InvestorRelations@nls-pharma.com
www.nlspharmaceutics.com
NLS Pharmaceutics (NASDAQ:NLSPW)
Historical Stock Chart
From Aug 2024 to Sep 2024
NLS Pharmaceutics (NASDAQ:NLSPW)
Historical Stock Chart
From Sep 2023 to Sep 2024